ALMS — Alumis Inc. Common Stock
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ
- Employees: 168
- Website: https://www.alumis.com
Latest SEC filings for ALMS
- 8-K — 2026-09-01
- 10-Q — 2026-08-13
- 8-K — 2026-08-13
- 8-K — 2026-08-10
- 8-K — 2026-07-02
- 8-K — 2026-06-29
- ARS — 2026-05-18
- 10-Q — 2026-05-14
- 8-K — 2026-05-14
- 8-K — 2026-03-30
Latest ALMS news
- — Alumis Inc. (NASDAQ:ALMS) Stock Has Consensus Target Price of $33.27 (defenseworld.net)
- — Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures (globenewswire.com)
Educational tool only — not investment advice.